# A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma

> **NCT00434434** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **DRUG:** omalizumab
- **DRUG:** omalizumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00434434
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-02
- **Final completion:** 2009-06
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434434, "A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00434434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*